SCHEDULE: Soleus Capital Amends NeuroPace Stake to 7.0%

Soleus Capital Management and its affiliates have filed an Amendment No. 5 to their Schedule 13G, reporting a combined beneficial ownership of 7.0% in NeuroPace, Inc. common stock.

Summary

• Soleus Capital Management, L.P., along with its affiliates Soleus Private Equity Fund I, L.P. and Soleus Capital Master Fund, L.P., reported beneficial ownership of 2,303,828 shares of NeuroPace, Inc. common stock.
• This aggregate ownership represents 7.0% of NeuroPace's outstanding common stock.
• The percentage is calculated based on 32,798,505 shares of common stock outstanding as of May 9, 2025.
• Soleus Private Equity Fund I, L.P. directly holds 310,321 shares, representing 0.9% of the class.
• Soleus Capital Master Fund, L.P. directly holds 1,993,507 shares, representing 6.1% of the class.
• Guy Levy, as the sole managing member of key entities within the Soleus structure, is also reported as beneficially owning 2,303,828 shares, representing 7.0% of the class.

Sentiment

Score: 5

Explanation: The filing is a routine amendment to a Schedule 13G, reporting an updated beneficial ownership stake. Without comparison to previous filings, it is neutral in sentiment regarding the company's performance or outlook, simply disclosing an investor's position.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Confirms a significant institutional investor's continued stake in NeuroPace, Inc., potentially signaling long-term interest to other shareholders.

Key Dates

Keywords

NeuroPace, Soleus Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Medical Devices, Neurology